Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Lesma, Elena ^a   Grande, Vera ^a   Ancona, Silvia ^a   Carelli, Stephana ^a   Di Giulio, Anna Maria ^a   Gorio, Alfredo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; SMALL INTERFERING RNA; TRANSFER RNA; TUBERIN; WORTMANNIN; ANTIBODY; EGFR PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SMOOTH MUSCLE FIBER; TUBEROUS SCLEROSIS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BIOLOGICAL MODEL; CELL CULTURE; DRUG EFFECT; EVALUATION; GENETICS; IMMUNOLOGY; LYMPHANGIOLEIOMYOMATOSIS; METABOLISM; MUSCLE TUMOR; PATHOLOGY; PHYSIOLOGY; VASCULAR SMOOTH MUSCLE;

ADULT; ANTIBODIES; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMOOTH MUSCLE TUMOR; TRANSFECTION; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 55849129236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003558     Document Type: Article

References (35)

1. Young J, Povey S (1998) The genetic basis of tuberous sclerosis. Mol Med Today 4: 313-319.
2. Janssen LAJ, Sampson JR, van der Est M, Deelen W, Verhoef S, et al. (1994) Refined localization of TSC1 by combined analysis of 9q34 and 16p13 data in 14 tuberous sclerosis families. Hum Genet 94: 437-440.
3. European Chromosome 16 Tuberous Sclerosis Consortium (1993) Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75: 1305-1315.
4. Gomez MR (1999) Tuberous Sclerosis, 3rd Ed. New York: Oxford University Press. 10 p.
5. Kenerson HL, Aicher LD, True LD, Yeung RS (2002) Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res 62: 5645-5650.
6. van Slegtenhorst M, Nellist M, Nagelkerken B, Cheadle J, Snell R, et al. (1998) Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7: 1053-1057.
7. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, et al. (2002) Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the Tsc2 tumor suppressor gene in pulmonary lymphangeioleiomyomatosis (LAM). J Biol Chem 277: 30958-30967.
8. Kwiatkowski DJ, Zhang H, Bandura JL, Heiberger KM, Glogauer M, et al. (2002) El-Hashemite, and Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 11: 525-534.
9. Gingras AC, Raught B, Sonenberg N (1999) eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 68: 913-963.
10. Takata M, Ogawa W, Kitamura T, Hino Y, Kuroda S (1999) Requirement for Akt (protein kinase B) in insulin-induced activation of glycogen synthase and phosphorylation of 4E-BP1 (PHAS-1). J Biol Chem 274: 20611-20618.
11. Karbowniczek M, Cash T, Cheung M, Robertson GP, Astrinidis A, et al. (2004) Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J Biol Chem 279: 29930-29937.
12. Roux PP, Ballif BA, Anjum R, Gygi SP, Blenis J (2004) Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. PNAS 101: 13489-13494.
13. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk: implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
14. Han S, Santos TM, Puga A, Roy J, Thiele EA, et al. (2004) Phosphorylation of tuberin as a novel mechanism for somatic inactivation of the tuberous sclerosis complex proteins in brain lesions. Cancer Res 64: 812-816.
15. Lesma E, Grande V, Carelli S, Brancaccio D, et al. (2005) Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: EGF is the required growth factor. Am J Pathol 167: 1093-1103.
16. Carelli S, Lesma E, Paratore S, Grande V, Zadra G, et al. (2007) Survivin expression in tuberous sclerosis complex cells. Mol Med 13: 166-77.
17. Arbiser JL, Yeung R, Weiss SH, Arbiser ZK, Amin MB, et al. (2001) The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma. Am J Pathol 159: 483-491.
18. Astrinidis A, Cash TP, Hunter DS, Walker CL, Chernoff J (2002) Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21: 8470-8476.
19. Bagby SP, Kirk EA, Mitchell LH, O'Reailly MM, Holden WE, et al. (1993) Proliferative synergy of ANG II and EGF in porcine aortic vascular smooth cells. Am J Physiol 265: F239-F249.
20. Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657.
21. Karbowniczek M, Yu J, Henske EP (2003) Renal angiomyolipomas from patients with sporadic lymphangiomyomatosis contain both neoplatic and nonneoplastic vascular structures. Am J Pathol 162: 491-500.
22. El-Hashemite N, Walker V, Kwiatkowski DJ (2005) Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 15;65: 2474-81.
23. Kuemmerle JF, Bushman TL (1998) IGF-I stimulates intestinal muscle cell growth by activating distinct PI 3-kinase and MAP kinase pathways. Am J Gastrointest Liver Physiol 275: G151-G158.
24. Powis G, Bonjouklian R, Berggren MM, Gallegos A, Abraham R, et al. (1994) Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Canc Res 54: 2419-2423.
25. 2 activity in Swiss 3T3 cells. J Biol Chem 270: 25352-25355.
26. Perugini RA, McDade TP, Vittimberga Jr FJ, Callery MP (2000) Pancreatic cancer cell proliferation is phosphatidylinositol 3-kinase dependent. J Surg Res 90: 39-44.
27. Stambolic V, Suzuki A, de la Pompa JL, Brothrs GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
28. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223-1233.
29. Kuemmerle JF, Zhou H, Bowers JG (2004) IGF-I stimulates human intestinal smooth muscle cell growth by regulation of G1 phase cell cycle proteins. Am J Gastrointest Liver Physiol 286: G412-419.
30. Vokes EE, Chu E (2006) Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology 20(5 Suppl 2): 15-25.
31. Harwood FC, Shu L, Houghton PJ (2008) mTORC1 signaling can regulate growth factor activation of p44/42 mitogen activated protein kinases through protein phosphatase 2A. J Biol Chem 283: 2575-85.
32. Kenerson HL, Dundon TA, Yeung RS (2005) Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatric Res 57: 67-75.
33. Lee L, Sudentas P, Donohue B, Asrican K, Worku A (2005) Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42: 213-227.
34. Bissler J, McCormack FX, Young LR, Elwing JM, Chuck G (2008) Sirolimus for Angiomyolipoma in Tuberous Sclerosis Complex or Lymphangioleiomyomatosis. N Engl J Med 358: 140-151.
35. Peng XD, Xu PZ, Chen ML, Hahn-Windgassen A, Skeen J, et al. (2003) Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 17: 1352-1365.